Andreas has, as of the first of May 2018, started as CEO, with our former CEO, Anders Weber, shifting to the position of CSO.
Andreas comes to RSP with over 17 years of experience as CEO in four different biotech companies, having successfully taken two of these companies to an exit. Andreas’ most recent success is his former company, NEO New Oncology, sold to Siemens in 2016. This highly innovative company developed a diagnostic kit that was CE marked to analyze tumors in order to enable the best possible treatment for patients.
As a person, Andreas is visionary and passionate about bringing the first non-invasive glucose sensor to the market. We are excited to have Andreas on board and know that we will benefit greatly from his extensive experience as we move forward in our clinical trials and towards market entry.
Anders, in his new role as CSO, will be focusing on assisting Andreas in developing and implementing RSP’s strategic goals.